Standard
Harvard
Fogd, K
, Bøgsted, M, Larsen, SF, Høholt, H, Jensen, A-M, Madsen, LH, Nyegaard, M, Sørensen, S, Holst, JM
, Schmitz, A, Johnsen, HE & Dybkær, K 2010, '
Screening for sensitivity towards vincristine and doxorubicin in a newly established B-cell cancer cell line panel revealed great variability in the dose resulting in 50% growth inhibition (GI50)', Forskningens Dag 2010 - Aalborg Sygehus, Aalborg,
28/10/2010 -
28/10/2010.
APA
Fogd, K.
, Bøgsted, M., Larsen, S. F., Høholt, H., Jensen, A-M., Madsen, L. H., Nyegaard, M., Sørensen, S., Holst, J. M.
, Schmitz, A., Johnsen, H. E., & Dybkær, K. (2010).
Screening for sensitivity towards vincristine and doxorubicin in a newly established B-cell cancer cell line panel revealed great variability in the dose resulting in 50% growth inhibition (GI50). Poster session præsenteret ved Forskningens Dag 2010 - Aalborg Sygehus, Aalborg.
CBE
Fogd K
, Bøgsted M, Larsen SF, Høholt H, Jensen A-M, Madsen LH, Nyegaard M, Sørensen S, Holst JM
, Schmitz A, et al. 2010.
Screening for sensitivity towards vincristine and doxorubicin in a newly established B-cell cancer cell line panel revealed great variability in the dose resulting in 50% growth inhibition (GI50). Poster session præsenteret ved Forskningens Dag 2010 - Aalborg Sygehus, Aalborg.
MLA
Vancouver
Author
Bibtex
@conference{726065515e584f5188ab7cc99cd9ca84,
title = "Screening for sensitivity towards vincristine and doxorubicin in a newly established B-cell cancer cell line panel revealed great variability in the dose resulting in 50% growth inhibition (GI50)",
author = "Kirsten Fogd and Martin B{\o}gsted and Larsen, {Steffen Falgreen} and H H{\o}holt and Ann-Maria Jensen and Madsen, {L H} and Mette Nyegaard and Suzette S{\o}rensen and Holst, {J M} and Alexander Schmitz and Johnsen, {Hans Erik} and Karen Dybk{\ae}r",
year = "2010",
language = "English",
note = "Forskningens Dag 2010 - Aalborg Sygehus ; Conference date: 28-10-2010 Through 28-10-2010",
}
RIS
TY - CONF
T1 - Screening for sensitivity towards vincristine and doxorubicin in a newly established B-cell cancer cell line panel revealed great variability in the dose resulting in 50% growth inhibition (GI50)
AU - Fogd, Kirsten
AU - Bøgsted, Martin
AU - Larsen, Steffen Falgreen
AU - Høholt, H
AU - Jensen, Ann-Maria
AU - Madsen, L H
AU - Nyegaard, Mette
AU - Sørensen, Suzette
AU - Holst, J M
AU - Schmitz, Alexander
AU - Johnsen, Hans Erik
AU - Dybkær, Karen
PY - 2010
Y1 - 2010
M3 - Poster
T2 - Forskningens Dag 2010 - Aalborg Sygehus
Y2 - 28 October 2010 through 28 October 2010
ER -